Actively Recruiting
tDCS to Decrease Opioid Relapse (UH3)
Led by Butler Hospital · Updated on 2024-12-04
100
Participants Needed
1
Research Sites
141 weeks
Total Duration
On this page
Sponsors
B
Butler Hospital
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.
CONDITIONS
Official Title
tDCS to Decrease Opioid Relapse (UH3)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Current opioid dependence
- Age between 21 and 60 years
- Recently started buprenorphine or methadone treatment (within 30 days)
- Enrolled in Butler Hospital treatment programs or receiving opioid treatment services in the community
You will not qualify if you...
- Diagnosis of organic brain disorders such as Parkinson's, Huntington's, multiple sclerosis, intracranial mass or infection, or hydrocephalus
- Bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, or current psychosis
- Current suicidality
- Significant neurocognitive dysfunction
- Medical conditions increasing tDCS risks, including seizure disorder, nonremovable intracranial metal objects (except dental fillings/implants), scalp skin disease or active lesions, active migraine or headache disorder, recent traumatic brain injury or skull fracture (within 1 year), or implanted medical devices interacting with electromagnetic fields
- Current probation or parole requirements or planned moves interfering with study participation
- Planning to stop buprenorphine or methadone treatment within less than 3 months
- Current pregnancy or plans to become pregnant within the next month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Butler Hospital
Providence, Rhode Island, United States, 02906
Actively Recruiting
Research Team
A
Ana M Abrantes, Ph.D.
CONTACT
J
Julie A Desaulniers, M.S.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here